Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy

Bispecific antibodies (bsAb) that bridge tumor cells and CD3-positive effector T cells are being developed against many tumor cell targets. While tumor cell factors other than target expression level appear to play a role in determining the efficacy of CD3 bsAb, the identity of such factors remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Decker, Corinne E., Young, Tara, Pasnikowski, Elizabeth, Chiu, Joyce, Song, Hang, Wei, Yi, Thurston, Gavin, Daly, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934601/
https://www.ncbi.nlm.nih.gov/pubmed/31882897
http://dx.doi.org/10.1038/s41598-019-56670-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934601/
https://www.ncbi.nlm.nih.gov/pubmed/31882897
http://dx.doi.org/10.1038/s41598-019-56670-x

Ejemplares similares